Henry Fechner

Induction of coxsackievirus-adenovirus-receptor expression during myocardial tissue formation and remodeling: identification of a cell-to-cell contact-dependent regulatory mechanism.

Molecular genetic and expression analysis of alpha-tocopherol transfer protein mRNA in German shepherd dogs with degenerative myelopathy.

Regulation of human factor IX expression using doxycycline-inducible gene expression system.

Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression.

Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses.

An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.

Gene therapy for gastric cancer: is it promising?

A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication.

Dimethyl sulfoxide enhances doxycycline-dependent protein expression in Tet-On cells.

Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma.

Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy.

Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy.

Inhibition of picornaviruses by means of RNA interference.

Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3.

Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus.

Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38.

Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor.

Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.

Rapid construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30.

Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions.

Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.

Matricellular signaling molecule CCN1 attenuates experimental autoimmune myocarditis by acting as a novel immune cell migration modulator.

Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).

Decreased cardiac SERCA2 expression, SR Ca uptake, and contractile function in hypothyroidism are attenuated in SERCA2 overexpressing transgenic rats.

Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions.

Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.

Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.

Roles of E4orf6 and VA I RNA in adenovirus-mediated stimulation of human parvovirus B19 DNA replication and structural gene expression.

Application of Mutated miR-206 Target Sites Enables Skeletal Muscle-specific Silencing of Transgene Expression of Cardiotropic AAV9 Vectors.

Adenovirus vector-mediated RNA interference for the inhibition of human parvovirus B19 replication.

A novel method for the quantification of adeno-associated virus vectors for RNA interference applications using quantitative polymerase chain reaction and purified genomic adeno-associated virus DNA as a standard.

A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum.

Interspecies differences in virus uptake versus cardiac function of the coxsackievirus and adenovirus receptor.

Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.

Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.

Impaired Endothelial Regeneration Through Human Parvovirus B19-Infected Circulating Angiogenic Cells in Patients With Cardiomyopathy.

Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir.

Use of a three-dimensional humanized liver model for the study of viral gene vectors.

Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.

The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection.

Biological antivirals for treatment of adenovirus infections.

MicroRNA-regulated viral vectors for gene therapy.